Improved microvascular blood flow, reduced inflammation and lack of activation of angiogensis by MAT.Ang-1 post-treatment in our nonlethal in vivo model of sepsis provide the basis for further clinical investigation with septic patients. The gene discussed is ANGPT1; the disease is Sepsis.